AdvanSix navigates headwinds with 7% sales growth amid Q1 net loss
AdvanSix (NYSE:ASIX) reported first-quarter 2026 financial results that reflected a resilient top line despite significant operational and macroeconomic hurdles.

Finance journalist at Grafa with years of experience covering Asia-Pacific financial markets at S&P Global, Mortgage Ezy, and GMA Network.
AdvanSix (NYSE:ASIX) reported first-quarter 2026 financial results that reflected a resilient top line despite significant operational and macroeconomic hurdles.
Century Casinos (NASDAQ:CNTY) delivered a record-breaking performance for the opening quarter of 2026, signaling that its recent capital investments and geographic diversification are beginning to yield higher operational efficiency.
BioArctic announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental Biologics License Application (sBLA) for Leqembi Iqlik (lecanemab-irmb).
QBE Insurance Group (ASX:QBE) reported 11% premium growth to $9.2 billion in Q1 FY26, reaffirming its positive annual outlook.
The RBA warns of two years of financial strain as rising fuel prices drive inflation, impacting groceries, construction, and household budgets across Australia.
Developers behind the NEAR Protocol warned that future quantum computing attacks could create a broader ownership verification crisis across blockchain ecosystems beyond simply compromising private keys.
Bitcoin and major cryptocurrencies retreated during Asian trading on Thursday as investor appetite shifted towards global equities amid growing optimism over a potential ceasefire agreement between the United States and Iran.
Labor mandates a 20% domestic gas reservation for east coast exporters to lower energy prices and secure local supply starting July 2027.
Zcash rallied nearly 30% over 24 hours to $543 during Asian trading on Tuesday, extending its monthly gain to more than 110% amid surging demand for privacy-focused cryptocurrencies.
PYC Therapeutics (ASX:PYC) announced the dosing of the first patient in the Phase 1b multiple ascending dose study of PYC-003.